Detailed Narrative
Q1 FY26 Financial Performance Overview
Aarti Drugs reported a robust Q1 FY26, with total revenues growing 6% year-on-year to INR591 crores. The API business contributed significantly, growing 5% year-on-year. Gross profit margins saw a healthy improvement of 130 basis points, reaching 36.8%, primarily due to input cost normalization. This translated into a 12% year-on-year increase in EBITDA to INR74 crores, with EBITDA margins improving to 12.6%.
Capacity Expansion & Backward Integration
The company's greenfield project at Sayakha, Gujarat, focused on backward integration for anti-diabetic products and their intermediates, has commenced trial production. This facility is expected to contribute to financials from Q3 FY26, aiming to improve profit margins and reduce input cost volatility. Additionally, the Tarapur greenfield site, producing salicylic acid, is ramping up operations, targeting 800 tonnes per month soon and eventually 1,600 tonnes per month, despite current output being below 200 tonnes/month.
Regulated Market Expansion & USFDA Approvals
Aarti Drugs achieved significant milestones with USFDA approval for its oncology facility and UK MHRA approval for its oral solid dosage (OSD) facility. These approvals are crucial for driving growth in regulated markets, with commercial supplies from the USFDA-approved Tarapur API facility expected to commence within 9-12 months. The company is also actively developing and registering new oncology dossiers globally, with 10 oncology products targeted for R&D completion by December 2026.
Formulation Business Growth & Product Mix Shift
The formulation business grew 14% year-on-year to INR80 crores in Q1 FY26, with 57% of this revenue from exports. Management projects this segment to almost double, reaching INR550-600 crores by FY28, driven by oncology and other OSD registrations. The overall product mix is expected to evolve, with Spec Chem and Intermediates potentially increasing their share from 8% to 15% within 3-4 years, while API contribution stabilizes around 70-75%.
Capital Allocation & Debt Management
Capex for Q1 FY26 stood at INR48.5 crores, with a full-year guidance of INR150-200 crores. Approximately 80-85% of this capex is allocated towards growth initiatives, including R&D for new formulations and brownfield expansions. Despite significant capex and shareholder payouts (INR80-85 crores annually), consolidated net debt remains controlled at INR597 crores, translating to a healthy debt-to-equity ratio of 0.42-0.43, well within the target range of 0.4-0.7.
Salicylic Acid Business Challenges & Strategy
The salicylic acid business faces challenges from Chinese dumping, which has led to a 6-7% price reduction from January to July, making it difficult to achieve profitability. The company is currently expensing costs from this plant, impacting current EBITDA. However, management is pursuing anti-dumping duties and believes that at higher utilization levels (1,500-1,600 tonnes/month), the plant will become profitable, with the diversified product basket helping absorb current losses.
Outlook on Margins and Growth
Management anticipates further improvement in EBITDA margins, targeting 15-16% by FY27, driven by better capacity utilization, normalized API pricing, and higher-value export opportunities. For FY26 and FY27, the company projects a 15% CAGR volume growth. While H1 FY26 is expected to see a negative price variation of 4-6%, this is forecasted to normalize in H2, leading to 10-15% value growth in the second half of FY26 and for FY27.